comprehensive -WSS

comprehensive

author：knowledge 2025-09-03 03:42:42 - browse：8

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Designating disabled people as health disparity population is crucial

hotspot

focus

WSS

Biogen joins immunology wave with $1.15 billion acquisition of HI

Doulas covered by Medicaid under New York's new plan

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Generative AI mines health records to identify patients’ social needs

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Fentanyl is making it harder to start addiction treatment

hotspot

comprehensive

knowledge

Sports medicine is finally prioritizing gender equality

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

The cancer drug shortage isn’t new — and neither are the solutions

Three issues to watch in global health in 2024

BioMarin wins approval for gene therapy to treat hemophilia A

Study finds gene variants tied to breast cancer risk in Black women

Medical leaders decry Supreme Court decision on affirmative action

New menopause drug shows promise in relief for hot flashes

Activists slam private health insurers over coverage restrictions

How I ended up pumping milk in a bathroom stall at JPM 2024

Wikipedia

Heart disease and mental health: A look at cardiac psychology

Reports of telehealth's death have been greatly exaggerated

Heart disease and mental health: A look at cardiac psychology

Making the case for fair compensation in clinical trials

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

The SUPPORT Act is critical to fighting the opioid crisis

hotspot

focus

focus

hotspot